Thyroid Cancer in a Psoriatic Patient Treated With Secukinumab: A Case Report and Literature Review.
증례보고
1/5 보강
Biologics are a key treatment option for managing chronic inflammatory and autoimmune diseases, especially moderate to severe psoriasis.
APA
Alyousef A, Attia H, et al. (2025). Thyroid Cancer in a Psoriatic Patient Treated With Secukinumab: A Case Report and Literature Review.. Cureus, 17(9), e93590. https://doi.org/10.7759/cureus.93590
MLA
Alyousef A, et al.. "Thyroid Cancer in a Psoriatic Patient Treated With Secukinumab: A Case Report and Literature Review.." Cureus, vol. 17, no. 9, 2025, pp. e93590.
PMID
41179072 ↗
Abstract 한글 요약
Biologics are a key treatment option for managing chronic inflammatory and autoimmune diseases, especially moderate to severe psoriasis. While studies have not definitively proven a causal link between biologics and cancer, concerns remain regarding their potential association with an increased risk of certain malignancies. This report describes an observed temporal association in a patient with psoriasis who was treated with the interleukin-17A inhibitor secukinumab for four years and subsequently developed metastatic medullary thyroid cancer.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Prostate Cancer Care for Men with an Intellectual Disability: A Population-based Cohort Study of Symptoms, Diagnosis, Treatment, and Survival.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Association between polygenic risk scores and cardiovascular events in prostate cancer patients receiving androgen deprivation therapy in Han Chinese.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.